Berger Franklin M
Director at AVIR; Director at ESSA Pharma Inc.; Director at FIVE PRIME THERAPEUTICS INC, and 1 more
- Sold, on record
- $2.6M
- Dollars the filings state
- Form 4 sales
- 5
- Latest Dec 10, 2024
- Form 144 notices
- 1
- Proposed sales
- Companies
- 4
- Filed as an executive or holder
Companies
- AVIRAtea Pharmaceuticals, Inc.Director
- ESSA Pharma Inc.Director
- FIVE PRIME THERAPEUTICS INCDirector
- Immune Design Corp.Director
Sales by reason
Form 4 sales per year, every sale on record.
Sales by company
- AVIR401,272 shares
- ESSA Pharma Inc.272,840 shares
- FIVE PRIME THERAPEUTICS INC79,980 shares
- Immune Design Corp.50,000 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale Immune Design Corp.UnusualDec 16, 2016 2016
Sold 50,000 shares at $6.55 ($328k)
Berger Franklin M, Director
Sold 66.7% of holdings ($491k position)25,000 shares leftFirst sale on recordFiling
- 2 Form 4 sale FIVE PRIME THERAPEUTICS INCUnusualDec 3, 2019 +1082 days
Sold 79,980 shares at $3.97 ($317k)
Berger Franklin M, Director
Sold 94.1% of holdings ($337k position)5,000 shares leftFirst sale on recordFiling
- 3 Form 4 sale AVIRPlan not statedNov 14, 2022 +1077 days
Sold 41,666 shares at $5.15 ($215k)
Berger Franklin M, Director
Sold 5.1% of holdings ($4.2M position)778,353 shares leftFirst sale on recordFiling
- 4 Form 4 sale ESSA Pharma Inc.UnusualDec 21, 2022 +37 days
Sold 272,840 shares at $2.67 ($729k)
Berger Franklin M, Director
Sold 28.5% of holdings ($2.6M position)684,404 shares leftFirst sale on recordFiling
- 5 Form 144 notice AVIRNoticeDec 10, 2024 +720 days
Filed to sell 359,606 shares ($1M)
Berger Franklin M, Lead Independent Director
No 10b5-1 planFirst sale on recordFiling
- 6 Form 4 sale AVIRUnusualDec 10, 2024 same day
Sold 359,606 shares at $2.85 ($1M)
Berger Franklin M, Director
No 10b5-1 planSold 44.3% of holdings ($2.3M position)451,897 shares leftFirst sale on recordFollows a Form 144Filing
Every transaction
Loading transactions…
Sales and notices (6)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Dec 10, 2024 | Dec 12, 2024 | AVIR | Director | Form 4 sale | 359,606 | $1M | 44.3% | Unusual | SEC |
| Dec 10, 2024 | Dec 10, 2024 | AVIR | Lead Independent Director | Form 144 notice | 359,606 | $1M | Notice | SEC | |
| Dec 21, 2022 | Jan 5, 2023 | ESSA Pharma Inc. | Director | Form 4 sale | 272,840 | $729k | 28.5% | Unusual | SEC |
| Nov 14, 2022 | Nov 15, 2022 | AVIR | Director | Form 4 sale | 41,666 | $215k | 5.1% | Plan not stated | SEC |
| Dec 3, 2019 | Dec 4, 2019 | FIVE PRIME THERAPEUTICS INC | Director | Form 4 sale | 79,980 | $317k | 94.1% | Unusual | SEC |
| Dec 16, 2016 | Dec 20, 2016 | Immune Design Corp. | Director | Form 4 sale | 50,000 | $328k | 66.7% | Unusual | SEC |